Document is current
Any future updates will be listed below
-
Authors
Gossec, Laure
Walsh, Jessica A.
Sengupta, Raj
Bushmakin, Andrew G.
Cappelleri, Joseph C.
Yndestad, Arne
Dina, Oluwaseyi
Cella, David
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03502616 at ClinicalTrials.govDocuments that mention this clinical trial
POS1116 TIME TO IMPROVEMENT OF PAIN, MORNING STIFFNESS AND DISEASE ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH TOFACITINIB
https://doi.org/10.1136/annrheumdis-2023-eular.2417
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468
AB0750 Back pain and morning stiffness as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
https://doi.org/10.1136/annrheumdis-2022-eular.28
OP0239 PSYCHOMETRIC EVALUATION OF FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS
https://doi.org/10.1136/annrheumdis-2021-eular.62
POS0296 INTEGRATED SAFETY ANALYSIS OF TOFACITINIB IN ANKYLOSING SPONDYLITIS CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.2076
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
https://doi.org/10.1136/annrheumdis-2020-219601
POS0305 TIME TO IMPROVEMENT OF FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN A STUDY OF TOFACITINIB
https://doi.org/10.1136/annrheumdis-2022-eular.2391
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
https://doi.org/10.1136/ard-2023-223850
Improvement of Fatigue in Patients with Ankylosing Spondylitis Receiving Tofacitinib: Analyses of a Phase 3 Randomized Controlled Trial
https://doi.org/10.1007/s40744-024-00727-5
POS0895 EFFECT OF TOFACITINIB ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.106
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial
https://doi.org/10.1136/rmdopen-2022-002253
AB0937 TOFACITINIB EFFICACY AND SAFETY IN PATIENTS WITH ANKYLOSING SPONDYLITIS BY BASELINE C‑REACTIVE PROTEIN LEVELS: A POST HOC ANALYSIS
https://doi.org/10.1136/annrheumdis-2023-eular.2118
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 3 September 2024
Accepted: 11 November 2024
First Online: 13 December 2024
Declarations
:
: Laure Gossec has received grants or contracts from Pfizer Inc, Sandoz, and UCB, consulting fees from AbbVie, Bristol Myers Squibb, Celltrion, Galapagos, Janssen, Novartis, Pfizer Inc, and UCB, honoraria for lectures from AbbVie, Amgen, Eli Lilly, Galapagos, Gilead Sciences, Janssen, MSD, Pfizer Inc, Stada and UCB, support for attending meetings and/or travel from Janssen, Novartis, and UCB, and medical writing support from Janssen, Pfizer Inc, and UCB. Jessica A. Walsh has received grant support from AbbVie, Merck, and Pfizer Inc, and consulting fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB. Raj Sengupta has received grant support from AbbVie, Celgene, Novartis, and UCB, and speaker honoraria from AbbVie, Biogen, Celgene, Eli Lilly, Novartis, and UCB. Andrew G. Bushmakin, Joseph C. Cappelleri, Arne Yndestad, and Oluwaseyi Dina are employees of, and stockholders in, Pfizer Inc. David Cella has received consulting fees from AbbVie, Alexion Pharmaceuticals, Astellas Pharma, Bayer, Bristol Myers Squibb, Clovis Oncology, Evidera, Exelixis, Horizon Therapeutics, Janssen, Merck/Schering-Plough, National Academy of Sciences, Novartis Pharma K.K. (Japan), Pfizer Inc, PledPharma, and Regeneron, and has an ownership interest as President in FACIT.org.
: The trial was conducted in accordance with the International Council for Harmonisation Good Clinical Practice guidelines, local regulatory requirements, and the ethical principles of the Declaration of Helsinki. Patients provided written, informed consent, and the study protocol was approved by an Institutional Review Board or Independent Ethics Committee at each study site. Details of all study sites are listed in full on ClinicalTrials.gov []. The FACIT-F scale is owned and copyrighted by, and the intellectual property of, David Cella, PhD.
